Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Janus green B | Janus green B. Group: Biochemicals. Grades: Highly Purified. CAS No. 2869-83-2. Pack Sizes: 2g, 5g, 10g, 25g, 50g. Molecular Formula: C30H31ClN6. US Biological Life Sciences. |  Worldwide |
| Janus green B | Janus green B is a supravital stain. Janus green B staining reaction is oxygen dependent, and is reversibly inhibited by cyanide. Janus green B has been used for staining peripheral nerves in live insects, lymphatic vessels of rabbits and mitochondria [1] [2] [3]. Uses: Scientific research. Group: Fluorescent dye. CAS No. 2869-83-2. Pack Sizes: 100 mg; 500 mg; 1 g; 5 g. Product ID: HY-D1122. |  |
| Janus Green B, 0.1% Aqueous, Laboratory Grade, 100 mL | Formula: C30H31ClN6. Formula Wt: 511. 07. Storage Code: Green; general chemical storage. Group: chem-category ph-indicators. Grades: chem-grade laboratory. CAS No. 2869-83-2. Product ID: 869573. -- SOLD FOR EDUCATIONAL USE ONLY -- |  |
| Janus Green B Certified ≥60% (Dye content) | Janus Green B Certified ≥60% (Dye content). Group: Biochemicals. Grades: Certified Dye. Pack Sizes: 5g, 25g, 100g, 250g. US Biological Life Sciences. | Worldwide |
| Janus green B (C.I. 11050) | 5g Pack Size. Group: Stains & Indicators. Formula: C30H31ClN6. CAS No. 2869-83-2. Prepack ID 58328236-5g. Molecular Weight 511.06. See USA prepack pricing. |  |
| 11-Deacetoxywortmannin | 11-Deacetoxywortmannin is an antibiotic produced by Aspergillus janus NRRL 3807 and Penicillum funiculosum NRRL 3363. It has a strong anti-fungal and anti-inflammatory effect, and has an anti-edema effect. Synonyms: 11-Desacetoxywortmannin. CAS No. 31652-69-4. Molecular formula: C21H22O6. Mole weight: 370.39. |  |
| 1-Benzyl-4-methyl-3-(methylamino)piperidine Dihydrochloride | A dihydrochloride salt form of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine;dihydrochloride; 1-benzyl-N,4-dimethylpiperidin-3-amine;dihydrochloride. Grades: 99 %. CAS No. 1228879-37-5. Molecular formula: C14H24Cl2N2. Mole weight: 291.26. | |
| 1-Benzyl-4-methyl-3-piperidinamine | 1-Benzyl-4-methyl-3-piperidinamine is an intermediate of Tofacitinib (T528000); an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases. Group: Biochemicals. Grades: Highly Purified. CAS No. 1039738-27-6. Pack Sizes: 250mg, 1g. Molecular Formula: C13H20N2, Molecular Weight: 204.31. US Biological Life Sciences. | Worldwide |
| ((1R,3R)-3-Amino-cyclopentyl)-carbamic Acid tert-Butyl Ester | ((1R,3R)-3-Amino-cyclopentyl)-carbamic Acid tert-Butyl Ester is used in the preparation of quinoline-3-carboxoamides as H-PGDS inhibitors as well as novel triazolo-pyrrolopyridines as Janus kinase 1 inhibitors. Group: Biochemicals. Grades: Highly Purified. CAS No. 1009075-44-8. Pack Sizes: 5mg, 10mg. Molecular Formula: C10H20N2O2, Molecular Weight: 200.28. US Biological Life Sciences. | Worldwide |
| 2,2-Dimethylcyclohexanone | 2,2-Dimethylcyclohexanone is a useful synthetic intermediate. It is used as a reagent to prepare 9-cis-retinoic acid ring-demethylated analogs. It is also used to prepare selective Janus kinase inhibitors for the treatment of autoimmune diseases and organ transplant rejection. Group: Biochemicals. Grades: Highly Purified. CAS No. 1193-47-1. Pack Sizes: 250mg, 1g. Molecular Formula: C8H14O. US Biological Life Sciences. | Worldwide |
| 2,5-Dimethylpyrrolidine | 2,5-Dimethylpyrrolidine is a building block that has been used as a reactant for the preparation of adenosine A2A/A1 receptor antagonists for the treatment of parkinsons disease and piperidinylamino pyrrolopyrimidine derivatives as selective Janus kinase inhibitors for the treatment of autoimmune diseases and organ transplant rejection. Group: Biochemicals. Grades: Highly Purified. CAS No. 3378-71-0. Pack Sizes: 50mg, 100mg. Molecular Formula: C6H13N, Molecular Weight: 99.17. US Biological Life Sciences. | Worldwide |
| 2-Chloro-N-methylacetamide | 2-Chloro-N-methylacetamide is an intermediate used to prepare piperidinylamino pyrrolopyrimidines as selective Janus kinase inhibitors for the treatment of autoimmune diseases and organ transplant rejection. Group: Biochemicals. Grades: Highly Purified. CAS No. 96-30-0. Pack Sizes: 1g, 5g. Molecular Formula: C3H6ClNO, Molecular Weight: 107.54. US Biological Life Sciences. | Worldwide |
| 3-((3R,4R)-4-methyl-3-(methylamino)piperidin-1-yl)-3-oxopropanenitrile hydrochloride | An impurity of Tofacitinib, a Janus kinase inhibitor that could be used against rheumatoid arthritis. CAS No. 1640971-87-4. Molecular formula: C10H18ClN3O. Mole weight: 231.72. | |
| 3-Amino-7-[[4-(dimethylamino)phenyl]azo]-5-phenylphenazinium chloride | 3-Amino-7-[[4-(dimethylamino)phenyl]azo]-5-phenylphenazinium chloride. Uses: Designed for use in research and industrial production. Additional or Alternative Names: EINECS 225-029-8; Janus Green G; Janus green. Product Category: Heterocyclic Organic Compound. CAS No. 4618-88-6. Molecular formula: C26H23ClN6. Mole weight: 454.954020 [g/mol]. Purity: 0.96. IUPACName: 8-[(4-dimethylaminophenyl)diazenyl]-10-phenylphenazin-10-ium-2-amine chloride. Product ID: ACM4618886. Alfa Chemistry ISO 9001:2015 Certified. |  |
| 6-Chloro-7-deazapurine | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: 4-Chloro-1H-pyrrolo[2,3-d]pyrimidine; 4-Chloropyrrolo[2,3-d]pyrimidine; NSC 64952. Grades: ≥98% by HPLC. CAS No. 3680-69-1. Molecular formula: C6H4ClN3. Mole weight: 153.57. | |
| AC410 | AC410 is a Janus kinase 2 (JAK2) inhibitor with Kd of 0.18 nM. AC410 is selective for JAK2 and Kd is 2.5 nM for JAK1 and 5nM for JAK3. Phase I for the treatment of Autoimmune disorders and Inflammation is on-going. Uses: Autoimmune disorders; inflammation. Synonyms: AC410; AC 410; AC-410; (S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol;1361415-86-2 (HCl). Grades: 98%. CAS No. 1361415-84-0. Molecular formula: C19H16FN5O. Mole weight: 349.40. | |
| ASN-002 | ASN-002 (Gusacitinib) is a dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with an IC50 value of 5-46 nM. It has anti-cancer activity. Synonyms: Gusacitinib. Grades: ≥98% by HPLC. CAS No. 1425381-60-7. Molecular formula: C24H28N8O2. Mole weight: 460.5. | |
| AT-9283 L-lactate | AT9283 is a multikinase inhibitor, is also a small-molecule inhibitor of several kinases with potential antineoplastic activity. AT9283 binds to and inhibits Aurora kinases A and B, JAK2 (Janus kinase 2) and the kinase BCR-ABL, which may result in the inhibition of cellular division and proliferation and the induction of apoptosis in tumor cells that overexpress these kinases. Synonyms: AT 9283; AT9283. CAS No. 896466-76-5. Molecular formula: C19H23N7O2. Mole weight: 471.52. | |
| AZD-1480 | AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. Synonyms: AZD1480; AZD-1480; AZD 1480. Grades: 0.98. CAS No. 935666-88-9. Molecular formula: C14H14ClFN8. Mole weight: 348.77. | |
| Benzyl 4-nitrophenyl carbonate | Benzyl 4-Nitrophenyl Carbonate is used as a reagent in the synthesis of Janus PEG-based dendrimers for use in combination therapy by controlled multi-drug loading and sequential release. Benzyl 4-Nitrophenyl Carbonate is also used as a reagent in the synthesis of Norfloxacin analogs which can exhibit antibacterial and antifungal activities under visible and UV light. Synonyms: Carbonic Acid Benzyl 4-Nitrophenyl Ester; BENZYL 4-NITROPHENYL CARBONATE; Carbonic Acid 4-Nitrophenyl Phenylmethyl Ester; Carbonic Acid Benzyl p-Nitrophenyl Ester; 4-Nitrophenyl Benzyl Carbonate; Benzyl p-Nitrophenyl Carbonate; NSC 171047; p-Nitrophenyl Benzyl Carbonate. Grades: 98 % (HPLC). CAS No. 13795-24-9. Molecular formula: C14H11NO5. Mole weight: 273.24. | |
| BMT-1438 | BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and other autoimmune diseases. It has a preference for JAK1 and JAK3. BMT-1438 showed excellent effect both in vitro and in a collagen-induced arthritis mouse model. Uses: The potential treatment of rheumatoid arthritis and other autoimmune diseases. Synonyms: BMT-1438; BMT 1438; BMT1438. | |
| Brepocitinib | Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC 50 s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC 50 s of 77 nM and 6.49 μM, respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PF-06700841. CAS No. 1883299-62-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112708. | |
| Cerdulatinib | Cerdulatinib, also known as PRT2070 and PRT062070, is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferentially inhibited JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types. IL2 mediated STAT5 Y694 was inhibited with an IC50 of 0.27uM, while IL4 mediated signaling to STAT6 Y641 and functional responses in B cells and monocytes, namely CD69, CD25, and CD23 up-regulation, were inhibited with IC50 within the range of 0.11uM to 0.57uM. It is currently being studied in patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations. Synonyms: Cerdulatinib; PRT2070; PRT-2070; PRT 2070; PRT-062070; PRT 062070; PRT062070. CAS No. 1198300-79-6. Molecular formula: C20H27N7O3S. Mole weight: 445.542. | |
| CP-690550A | This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, transplant rejection and other immune-mediated disorders. Uses: Immune-mediated disorders. Synonyms: CP-690550A; CP-690,550A; CP 690550A; CP690550A; Tofacitinib metabolite M2; UNII-Q7ZOK859UK; Tofacitinib metabolite M2; Q7ZOK859UK; CHEMBL1630791; 2-hydroxy-1-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone. Grades: 98%. CAS No. 1243290-37-0. Molecular formula: C15H21N5O2. Mole weight: 303.37. | |
| CP-690550 Citrate (Tofacitinib Citrate) | CP-690550 is a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis. Group: Biochemicals. Alternative Names: (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- β -oxo-1-piperidinepropane nitrile; 2-Hydroxy-1,2,3-propanetricarboxylate; (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-Hydroxy-1,2,3-propanetricarboxylate; CP 690500-10; CP 690550-10; Tofacitinib Citrate. Grades: Highly Purified. CAS No. 540737-29-9. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| Cyt387 | Cyt387 is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50 = 11 nM and 18 nM respectively). It has been shown to decrease cancer stem cell associated tumor burden in a mouse model of human ovarian cancer. It is commonly used as a therapy for myelofibrosis. Uses: An orally bioavailable small-molecule inhibitor of janus kinases 1 and 2 (jak1/2) with potential antineoplastic activity (ic50s = 11 and 18 nm, respectively). Synonyms: Momelotinib; N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide; CYT 11387; CYT 387; CYT-387; CYT387; CYT-0387; GS 0387. Grades: >98%. CAS No. 1056634-68-4. Molecular formula: C23H22N6O2. Mole weight: 414.46. | |
| Cytovaricin B | Cytovaricin B is a Janus kinase-signal transducer and activation protein (JAK-STAT) inhibitor produced by Streptamyces torulosus 3197-GM1. CAS No. 129985-88-2. Molecular formula: C48H82O16. Mole weight: 915.15. | |
| Dihydro Tofacitinib Citrate | An impurity of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: Tofacitinib Impurity; 5,6-Dihydro CP-690550 citrate; 5,6-Dihydro Tofacitinib citrate. Molecular formula: C22H30N6O8. Mole weight: 506.51. | |
| Ethynylcytidine | Ethynylcytidine is a synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule. Synonyms: ECyd; TAS-106; TAS 106; TAS106; 3'-C-Ethynylcytidine; AIDS241582; AIDS 241582; AIDS-241582; SB-596168; SB596168; SB 596168; 3'-Ethynylcytidine. CAS No. 180300-43-0. Molecular formula: C11H13N3O5. Mole weight: 267.241. | |
| Golidocitinib | Golidocitinib is a novel potent and selective janus kinase 1 (JAK1) inhibitor, with antineoplastic properties. Synonyms: (2R)-N-(3-{2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide; AZD-4205; AZD4205; AZD 4205; NSC801813; NSC-801813; 1-Piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha,4-dimethyl-, (alphaR)-; JAK1 inhibitor 3; Golidocitinibum. Grades: ≥98%. CAS No. 2091134-68-6. Molecular formula: C25H31N9O2. Mole weight: 489.58. | |
| Ilunocitinib | Ilunocitinib is a Janus kinase (JAK) inhibitor (veterinary use). Synonyms: {1-(cyclopropanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile; 3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-. CAS No. 1187594-14-4. Molecular formula: C17H17N7O2S. Mole weight: 383.43. | |
| Isodecyl Methacrylate | Isodecyl Methacrylate is a reagent used in the preparation of Janus particles which act as solid surfactants. Group: Biochemicals. Grades: Highly Purified. CAS No. 29964-84-9. Pack Sizes: 1g, 5g. Molecular Formula: N/A, Molecular Weight: US Biological Life Sciences. | Worldwide |
| JAK2 Inhibitor IV | JAK2 Inhibitor IV is a potent and selective Janus Kinase 2 (JAK2) inhibitor that inhibits the activity of both the wild-type JAK2 and the V617F mutant (IC50 = 78 and 206 nM, respectively). Synonyms: JAK2 inhibitor 13. Grades: 99%. CAS No. 1110502-30-1. Molecular formula: C17H20N4O2S. Mole weight: 344.43. | |
| JAK Inhibitor I (P6, DBI, (2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one, Pyridone 6, JAK1 Inhibitor I, JAK3 Inhibitor VII, JAK2 Inhibitor I) | A potent, reversible, cell-permeable, and ATP-competitive inhibitor of Janus protein tyrosine kinases (JAKs). Displays potent inhibitory activity against JAK1 (IC50=15nM for murine JAK1), JAK2 (IC50=1nM), JAK3 (Ki=5nM), and Tyk2 (IC50=1nM). Inhibits other kinases at much higher concentrations. Shown to inhibit IL2- and IL4-dependent proliferation of CTLL cells and block the phosphorylation of STAT5; and further induce growth inhibition of multiple myeloma cells expressing activated JAKs and STAT3, unlike AG 490. A 10mM solution of JAK Inhibitor I in DMSO is also available. Group: Biochemicals. Grades: Highly Purified. CAS No. 457081-03-7. Pack Sizes: 500ug, 1mg. US Biological Life Sciences. | Worldwide |
| JANEX-1 | A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50=78 μM). Has no effect on JAK1, JAK2, or Zap/Syk or Src tyrosine kinases. Acts as a potent inhibitor of glioblastoma cell adhesion and migration. Also reported to block thrombin-induced platelet aggregation. Synonyms: WHI-P131, WHI P-131, WHI P131, Janex 1. Grades: >98%. CAS No. 202475-60-3. Molecular formula: C16H15N3O3. Mole weight: 297.31. | |
| MS-1020 | MS-1020 is a selective, cell-permeable inhibitor of Janus kinase 3 (JAK3). It potently inhibited persistently-active STAT3 in a cell type-specific manner, and consistently suppressed interleukin-2-induced JAK3/STAT5 signalling. Synonyms: MS 1020; MS1020; 1-Hydroxy-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]naphthalene-2-carboxamide. Grades: ≥95%. CAS No. 1255516-86-9. Molecular formula: C21H18N2O3. Mole weight: 346.4. | |
| N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; N-methyl-N-[(3R,4R)-4-methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. CAS No. 477600-74-1. Molecular formula: C13H19N5. Mole weight: 245.32. | |
| non-specific protein-tyrosine kinase | Unlike EC 2.7.10.1, receptor protein-tyrosine kinase, this protein-tyrosine kinase does not have a transmembrane domain. In the human genome, 32 non-specific protein-tyrosine kinases have been identified and these can be divided into ten families. Group: Enzymes. Synonyms: ABL; ABL1; ABL2; ABLL; ACK1; ACK2; AGMX1; ARG; ATK; ATP:protein-tyrosine O-phosphotransferase (ambi. Enzyme Commission Number: EC 2.7.10.2. FAK. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3127; non-specific protein-tyrosine kinase; EC 2.7.10.2; ABL; ABL1; ABL2; ABLL; ACK1; ACK2; AGMX1; ARG; ATK; ATP:protein-tyrosine O-phosphotransferase (ambiguous); BLK; Bmk; BMX; BRK; Bruton's tyrosine kinase; Bsk; BTK; BTKL; CAKb; Cdgip; CHK; CSK; CTK; CYL; cytoplasmic protein tyrosine kinase; EMT; ETK; Fadk; FAK; FAK2; FER; Fert1/2; FES; FGR; focal adhesion kinase; FPS; FRK; FYN; HCK; HCTK; HYL; IMD1; ITK; IYK; JAK1; JAK2; JAK3; Janus kinase 1; Janus kinase 2; Janus kinase 3; JTK1; JTK9; L-JAK; LCK; LSK; LYN; MATK; Ntk; p60c-src protein tyrosine kinase; PKB; protein-tyrosine kinase (ambiguous); PSCTK; PSCTK1; PSCTK2; PSCTK4; PSCTK5; PTK2; PTK2B; PTK6; PYK2; RAFTK; RAK; Rlk; Sik; SLK; SRC; SRC2; SRK; SRM; SRMS; STD; SYK; SYN; Tck; TEC; TNK1; Tsk; TXK; TYK2; TYK3; YES1; YK2; ZAP70. Cat No: EXWM-3127. |  |
| NSC-33994 | NSC-33994 is novel inhibitor of JAK2 tyrosine kinase (Janus kinase 2 ). Janus kinase 2 (JAK2) plays a crucial role in the pathomechanism of myeloproliferative disorders and hematological malignancies. Group: Biochemicals. Alternative Names: 4, 4'-[ (1E) -1, 2-Diethyl-1, 2-ethenediyl]bis[2-[ (diethylamino) methyl]phenol; (E) -4, 4'- (1, 2-Diethyl-1, 2-ethenediyl) bis[2-[ (diethylamino) methyl]phenol. Grades: Highly Purified. CAS No. 82058-16-0. Pack Sizes: 50mg. US Biological Life Sciences. | Worldwide |
| Oclacitinib | Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family members by 50% at concentrations (IC50 's) ranging from 10 to 99 nM and did not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nm). Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nm). Oclacitinib also inhibited the function of JAK1-dependent cytokines involved in allergy and inflammation (IL-2, IL-4, IL-6, and IL-13) as well as pruritus (IL-31) at IC50 's ranging from 36 to 249 nm. Oclacitinib had minimal effects on cytokines that did not activate the JAK1 enzyme in cells (erythropoietin, granulocyte/macrophage colony-stimulating factor, IL-12, IL-23; IC50 's > 1000 nm). These results demonstrate that oclacitinib is a targeted therapy that selectively inhibits JAK1-dependent cytokines involved in allergy, inflammation, and pruritus and suggests these are the mechanisms by which oclacitinib effectively controls clinical signs associated with allergic skin disease in dogs. Synonyms: Cyclohexanemethanesulfonamide, N-methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, trans-; trans-N-Methyl-4- (methyl-7H-pyrrolo[2, 3-d]pyrimidin-4-ylamino) cyclohexanemethanesulfonamide; JAKi; PF 03394197. Grades: 98%. CAS No. 1208319-26-9. Molecular formula: C15H23N5O2S. Mole weight: 337.44. | |
| Oclacitinib Maleate | Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM). Synonyms: Cyclohexanemethanesulfonamide, N-methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, trans-, (2Z)-2-butenedioate (1:x); Apoquel; Oclacitinib maleate (1:x); PF 03394197-11; trans-N-Methyl-4- (methyl-7H-pyrrolo[2, 3-d]pyrimidin-4-ylamino) cyclohexanemethanesulfonamide maleate (1:x); N-methyl-1- ( (1r, 4r) -4- (methyl (7H-pyrrolo[2, 3-d]pyrimidin-4-yl) amino) cyclohexyl) methanesulfonamide maleate. Grades: ≥95%. CAS No. 1208319-27-0. Molecular formula: C15H23N5O2S.xC4H4O4. Mole weight: 337.44 (free base). | |
| Pyridone 6 | Pyridone 6 is a potent and selective inhibitor of JAK1, JAK2, JAK3, and Tyk2, displaying significantly weaker affinities for other protein tyrosine kinases. It was shown to block IL-2 and IL-4-dependent proliferation of mouse T-cell lymphoma cells. Synonyms: Pyridone 6; Pyridone-6; Pyridone6; CMP 6; JAK Inhibitor I; Janus-Associated Kinase Inhibitor I. Grades: >98%. CAS No. 457081-03-7. Molecular formula: C18H16FN3O. Mole weight: 309.34. | |
| Ropsacitinib | Ropsacitinib is a Janus kinase inhibitor. Synonyms: Tyk2-IN-8; PF-06826647; (1r,3r)-3-(cyanomethyl)-3-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl}cyclobutane-1-carbonitrile; trans-3-Cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile. Grades: 98% by HPLC. CAS No. 2127109-84-4. Molecular formula: C20H17N9. Mole weight: 383.4. | |
| Ruxolitinib-alkyne | Ruxolitinib-alkyne is a derivative of Ruxolitinib (R702000), which is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis. Ruxolitinib-alkyne is prepared as a racemic mixture. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 1mg, 5mg. Molecular Formula: C18H19N5, Molecular Weight: 305.38. US Biological Life Sciences. | Worldwide |
| Ruxolitinib-azide | Ruxolitinib-azide is a derivative of Ruxolitinib (R702000), which is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C17H20N8, Molecular Weight: 336.39. US Biological Life Sciences. | Worldwide |
| Ruxolitinib, Free Base | Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC50's of 2.7 and 4.5nm for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis. Group: Biochemicals. Alternative Names: (b-R)-b-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INCB018424, INC18424, NCB018424, NCB18424. Grades: Purified. CAS No. 941678-49-5. Pack Sizes: 5mg, 10mg, 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Sarcosine t-butyl ester hydrochloride | Sarcosine t-butyl ester hydrochloride is a reactant used in various syntheses. It was used in the preparation of sulfonamidoisoquinolinyl guanidines which are selective urokinase-type plasminogen activator inhibitors. Also used in the development of pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3). Synonyms: H-Sar-OtBu HCl; H-MeGly-OtBu HCl; N-α-Methylglycine t-butyl ester hydrochloride. CAS No. 136088-69-2. Molecular formula: C7H16ClNO2. Mole weight: 181.66. | |
| SD 1029 | SD 1029 is cel-permeable and selective inhibitor of JAK2. It directly abrogates the Jak-Stat3 signaling pathway in human cancer cells expressing constitutively active Stat, suggesting its potential for cancer therapy. Synonyms: JAK2 Inhibitor III; Janus-Associated Kinase 2 Inhibitor III; SD1029; SD-1029; 9-(3,4-dichlorophenyl)-2,7-bis[(dimethylamino)methyl]-3,4,5,6,7,9-hexahydro-2H-xanthene-1,8-dione dihydrobromide. CAS No. 118372-34-2. Molecular formula: C25H30Cl2N2O3·2HBr. Mole weight: 639.3. | |
| (S)-Ruxolitinib | Ruxolitinib S enantiomer, the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor to enter the clinic. It was initially developed to target the constitutive activation of the JAK-STAT pathway. It maintains its anti-JAK activity by competitive inhibition of the ATP-binding catalytic site of the kinase domain. It is well absorbed at above 95%. Synonyms: (S)-INCB018424; S-Ruxolitinib; SRuxolitinib; S Ruxolitinib; INCB-18424. Grades: >98%. CAS No. 941685-37-6. Molecular formula: C17H18N6. Mole weight: 306.37. | |
| Tofacitinib | Tofacitinib is a novel Janus kinase 3 (JAK3) inhibitor. JAK3 is a critical cytoplasmic tyrosine kinase in the signaling pathways of multiple cytokines (interleukin (IL)-2, -7, -15 and -21) that are associated with various T cell functions. Group: Biochemicals. Alternative Names: (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- β -oxo-1-piperidinepropane nitrile; 1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine; CP 690550; Tofacitinib. Grades: Highly Purified. CAS No. 936487-63-7. Pack Sizes: 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Tofacitinib Citrate Liposome | Tofacitinib Citrate (TOF) is a JAK3 inhibitor that achieves efficacy in treating rheumatoid arthritis by inhibiting the intracellular target Janus kinases (JAKs). This product is a pre-formulated liposome encapsulating Tofacitinib Citrate. It is only for research purposes. Group: Drug-loaded liposome. Categories: Niosomes, ethosomes, and transfersomes. |  |
| Tofacitinib Impurity C (Racimic Mixture) | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile. Molecular formula: C16H20N6O. Mole weight: 312.38. | |
| Tofacitinib Impurity I | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C14H22N2. 2HCl. Mole weight: 291.26. | |
| Tofacitinib Impurity J | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C14H22N2. 2HCl. Mole weight: 291.26. | |
| Tofacitinib Impurity K | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C16H22N5O3. Mole weight: 332.39. | |
| Tofacitinib Impurity L | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanamide; Tofacitinib Impurity 25; Tofacitinib impurity L; SCHEMBL17718764; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino)piperidin-1-yl)-3-oxopropanamide; CS-M2251; AKOS037650370; CS-14706; C12680. Molecular formula: C16H22N6O2. Mole weight: 330.39. | |
| Tofacitinib Impurity N | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N-methyl-N-((3s,4s)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine. CAS No. 1260614-73-0. Molecular formula: C13H19N5. Mole weight: 245.33. | |
| Tofacitinib Impurity (N-Des-(2-Cyanide-acetyl)-(3R,4S)) | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N-Des-(2-Cyanide-acetyl)-(3R,4S). Molecular formula: C13H19N5. Mole weight: 245.33. | |
| Tofacitinib Impurity (N-Des-(2-Cyanide-acetyl)-(3S,4R)) | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N-Des-(2-Cyanide-acetyl)-(3S,4R). Molecular formula: C13H19N5. Mole weight: 245.33. | |
| Tofacitinib Impurity O | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N-((3S,4S)-1-benzyl-4-Methylpiperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine. Molecular formula: C20H25N5. Mole weight: 335.46. | |
| Tofacitinib Impurity P | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: N-((3S,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine. CAS No. 1252883-90-1. Molecular formula: C20H25N5. Mole weight: 335.46. | |
| Tofacitinib Impurity R | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: 4-Chloro-7-tosyl-7h-pyrrolo[2,3-d]pyrimidine. CAS No. 479633-63-1. Molecular formula: C13H10ClN3O2S. Mole weight: 307.76. | |
| Tofacitinib Impurity S | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C27H31N5O2S. Mole weight: 489.64. | |
| Tofacitinib Impurity T | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C16H18N6O. Mole weight: 310.36. | |
| Tofacitinib Impurity U | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C13H18ClN5. Mole weight: 297.77. | |
| Tofacitinib Impurity V | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C16H19ClN6O. Mole weight: 346.82. | |
| Tofacitinib Impurity W | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C13H18ClN5. Mole weight: 279.77. | |
| Tofacitinib Impurity X | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C13H19N5. Mole weight: 245.33. | |
| Tofacitinib Impurity Y | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Molecular formula: C14H21N5. Mole weight: 259.36. | |
| Tofacitinib Impurity Z | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. Synonyms: 3-PiperidinaMine, 1-acetyl-N,4-diMethyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)-. CAS No. 477600-76-3. Molecular formula: C15H21N5O. Mole weight: 287.37. | |
Our database is helping our users find suppliers everyday.
